A Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) and Open Label Extension
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors PTC Therapeutics
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.
- 05 Jun 2017 Status changed from planning to not yet recruiting.
- 24 Nov 2016 New trial record